Patents by Inventor I-Ju Chen
I-Ju Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11944659Abstract: The invention provides a method for improving sarcopenia of a subject in need thereof by using Phellinus linteus, in which the method includes administering an effective dose of composition to the subject, and the composition includes Phellinus linteus (NITE BP-03321 and BCRC 930210) as an effective substance. By using the aforementioned composition including an extract of a fermented product of the Phellinus linteus and/or its derivative, diameters of myotubes, amounts of muscles and muscle muscular endurance can be maintained, thereby improving sarcopenia.Type: GrantFiled: October 12, 2021Date of Patent: April 2, 2024Assignee: GRAPE KING BIO LTDInventors: Chin-Chu Chen, I-Chen Li, Tsung-Ju Li, Ting-Yu Lu, Yen-Po Chen
-
Patent number: 11923205Abstract: A method for manufacturing a semiconductor device includes: providing a wafer-bonding stack structure having a sidewall layer and an exposed first component layer; forming a photoresist layer on the first component layer; performing an edge trimming process to at least remove the sidewall layer; and removing the photoresist layer. In this way, contaminant particles generated from the blade during the edge trimming process may fall on the photoresist layer but not fall on the first component layer, so as to protect the first component layer from being contaminated.Type: GrantFiled: December 17, 2021Date of Patent: March 5, 2024Assignee: UNITED MICROELECTRONICS CORPORATIONInventors: Kun-Ju Li, Ang Chan, Hsin-Jung Liu, Wei-Xin Gao, Jhih-Yuan Chen, Chun-Han Chen, Zong-Sian Wu, Chau-Chung Hou, I-Ming Lai, Fu-Shou Tsai
-
Publication number: 20240039569Abstract: A signal receiving method, comprising: receiving a first communication signal and/or a second communication signal through an antenna; when the antenna receives the first communication signal and the second communication signal simultaneously, transmitting, by a first receiving circuit, the first communication signal to a first amplifying circuit, and receiving the second communication signal by a second receiving circuit; and When the antenna does not receive the first communication signal and the second communication signal simultaneously, transmitting, by the first receiving circuit, the first communication signal to the first amplifying circuit, and transmitting, by the first receiving circuit, the second communication signal to a second amplifying circuit. The first communication signal and the second communication signal correspond to different communication protocols respectively.Type: ApplicationFiled: July 23, 2023Publication date: February 1, 2024Inventors: Ying-Rong SU, I-Ju CHEN, Kuan-Yu SHIH
-
Patent number: 11833223Abstract: Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to stage-specific embryonic antigen 4 (SSEA-4) are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as breast cancer, lung cancer, esophageal cancer, rectal cancer, biliary cancer, liver cancer, buccal cancer, gastric cancer, colon cancer, nasopharyngeal cancer, kidney cancer, prostate cancer, ovarian cancer, cervical cancer, endometrial cancer, pancreatic cancer, testicular cancer, bladder cancer, head and neck cancer, oral cancer, neuroendocrine cancer, adrenal cancer, thyroid cancer, bone cancer, skin cancer, basal cell carcinoma, squamous cell carcinoma, melanoma, and/or brain tumor.Type: GrantFiled: January 27, 2021Date of Patent: December 5, 2023Assignee: OBI PHARMA, INC.Inventors: Cheng-Der Tony Yu, Jiann-Shiun Lai, I-Ju Chen, Chiu-Chun Lin
-
Patent number: 11752204Abstract: The present invention provides vaccines comprising carbohydrate antigen conjugated to a diphtheria toxin (DT) as a carrier protein, wherein the ratio of the number of carbohydrate antigen molecule to the carrier protein molecule is higher than 5:1. Also disclosed herein is a novel saponin adjuvant and methods to inhibit cancer cells, by administering an effective amount of the vaccine disclose herein.Type: GrantFiled: November 1, 2019Date of Patent: September 12, 2023Assignee: OBI PHARMA INC.Inventors: Wei-Han Lee, Nan-Hsuan Wang, Chung-Hao Chang, Yih-Huang Hsieh, Cheng-Der Tony Yu, Cheng-Chi Wang, Yu-Hsin Lin, Yu-Chen Lin, I-Ju Chen
-
Patent number: 11643456Abstract: Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to Globo H, stage-specific embryonic antigen 3 (SSEA-3) and stage-specific embryonic antigen 4 (SSEA-4) are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as sarcoma, skin cancer, leukemia, lymphoma, brain cancer, glioblastoma, lung cancer, breast cancer, oral cancer, head-and-neck cancer, nasopharyngeal cancer, esophagus cancer, stomach cancer, liver cancer, bile duct cancer, gallbladder cancer, bladder cancer, pancreatic cancer, intestinal cancer, colorectal cancer, kidney cancer, cervix cancer, endometrial cancer, ovarian cancer, testical cancer, buccal cancer, oropharyngeal cancer, laryngeal cancer and prostate cancer.Type: GrantFiled: July 31, 2017Date of Patent: May 9, 2023Assignee: OBI PHARMA, INC.Inventors: Cheng-Der Tony Yu, Woan Eng Chan, Shu-Yu Lee, Jiann-Shiun Lai, I-Ju Chen
-
Patent number: 11642400Abstract: The present disclosure encompasses immunogenic/therapeutic compositions including Globo series antigens (SSEA-4, Globo H or SSEA-3) glycoconjugates and therapeutic adjuvants (OBI-821 or OBI-834) as well as methods of making and using the same to treat proliferative diseases such as cancer. The therapeutic conjugates include an antigen linked to a carrier. In particular, the therapeutic conjugates include a SSEA-4, Globo H or SSEA-3 moiety and a KLH moiety subunit linked via a linker. The therapeutic compositions are in part envisaged to act as cancer vaccines (single valent, bi-valent or tri-valent vaccines) for boosting the body's natural ability to protect itself, through the immune system from dangers posed by damaged or abnormal cells such as cancer cells. Exemplary immune response can be characterized by reduction of the severity of disease, including but not limited to, prevention of disease, delay in onset of disease, decreased severity of symptoms, decreased morbidity and delayed mortality.Type: GrantFiled: July 27, 2017Date of Patent: May 9, 2023Assignee: OBI PHARMA, INC.Inventors: Cheng-Der Tony Yu, Peiwen Yu, Kuo-Pao Lai, Wei-Han Lee, I-Ju Chen, Shu-Yi Lin, Yih-Huang Hsieh
-
Publication number: 20230056782Abstract: The present invention provides antibodies or the antigen-binding portion thereof, that bind to stage-specific embryonic antigen 3 (SSEA-3) antigen. Also disclosed herein are pharmaceutical compositions and methods for the inhibition of cancer cells in a subject in need thereof. The pharmaceutical compositions include an antibody or an antigen-binding portion thereof and at least one pharmaceutically acceptable carrier.Type: ApplicationFiled: December 30, 2020Publication date: February 23, 2023Inventors: MING-TAIN LAI, JIANN-SHIUN LAI, CHIU-CHUN LIN, I-JU CHEN, WOAN-ENG CHAN
-
Patent number: 11262060Abstract: A light source device includes a substrate, an electrode layer and an annular step-like surrounding frame both disposed on the substrate, a light emitter and a light detector both spaced apart from each other and mounted on the electrode layer in the surrounding frame, and a light permeable member disposed on the surrounding frame. The surrounding frame includes an upper tread arranged away from the substrate, an upper riser connected to an inner edge of the upper tread, a lower tread arranged at an inner side of the upper riser, and a lower riser connected to an inner edge of the lower tread and arranged away from the upper tread. The surrounding frame has a notch recessed in the lower tread and the lower riser for spatially communicating an inner side of the surrounding frame to an external space.Type: GrantFiled: August 8, 2019Date of Patent: March 1, 2022Assignees: LITE-ON OPTO TECHNOLOGY (CHANGZHOU) CO., LTD., LITE-ON TECHNOLOGY CORPORATIONInventors: Hsin-Wei Tsai, I-Ju Chen, Hou-Yen Tsao, Shu-Hua Yang, Yu-Hung Su
-
Patent number: 11236154Abstract: The present invention provides antibodies or the antigen-binding portion thereof to a tumor-associate carbohydrate antigen. Also disclosed herein are pharmaceutical compositions and methods for the inhibition of cancer cells in a subject in need thereof. The pharmaceutical compositions comprise an antibody or an antigen-binding portion thereof and at least one pharmaceutically acceptable carrier.Type: GrantFiled: August 21, 2019Date of Patent: February 1, 2022Assignee: OBI PHARMA INC.Inventors: Cheng-Der Tony Yu, Jiann-Shiun Lai, I-Ju Chen
-
Patent number: 11205731Abstract: A light source package structure is provided. The light source package structure includes a substrate, an upper electrode layer, a light emitting unit, a photodiode, a surrounding wall, a light permeable element, and a coating layer. The substrate includes a first surface and a second surface that is opposite to the first surface. The upper electrode layer is disposed on the first surface of the substrate. The light emitting unit and the photodiode both are disposed on the upper electrode layer. The surrounding wall is disposed on the first surface and is arranged to surround the light emitting unit and the photodiode. The light permeable element is disposed on the surrounding wall. The coating layer is disposed inside of the surrounding wall and is coated on a part of the first surface and a part of the upper electrode layer.Type: GrantFiled: May 5, 2020Date of Patent: December 21, 2021Assignees: LITE-ON OPTO TECHNOLOGY (CHANGZHOU) CO., LTD., LITE-ON TECHNOLOGY CORPORATIONInventors: Wen Lee, Hsiang-Chih Hung, I-Ju Chen, Shu-Hua Yang, Yu-Hung Su
-
Publication number: 20210284719Abstract: Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to Globo H, stage-specific embryonic antigen 3 (SSEA-3) and stage-specific embryonic antigen 4 (SSEA-4) are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as sarcoma, skin cancer, leukemia, lymphoma, brain cancer, glioblastoma, lung cancer, breast cancer, oral cancer, head-and-neck cancer, nasopharyngeal cancer, esophagus cancer, stomach cancer, liver cancer, bile duct cancer, gallbladder cancer, bladder cancer, pancreatic cancer, intestinal cancer, colorectal cancer, kidney cancer, cervix cancer, endometrial cancer, ovarian cancer, testical cancer, buccal cancer, oropharyngeal cancer, laryngeal cancer and prostate cancer.Type: ApplicationFiled: July 31, 2017Publication date: September 16, 2021Inventors: Cheng-Der Tony YU, Woan Eng CHAN, Shu-Yu LEE, Jiann-Shiun LAI, I-Ju CHEN
-
Publication number: 20210228732Abstract: Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to stage-specific embryonic antigen 4 (SSEA-4) are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnositcs. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as breast cancer, lung cancer, esophageal cancer, rectal cancer, biliary cancer, liver cancer, buccal cancer, gastric cancer, colon cancer, nasopharyngeal cancer, kidney cancer, prostate cancer, ovarian cancer, cervical cancer, endometrial cancer, pancreatic cancer, testicular cancer, bladder cancer, head and neck cancer, oral cancer, neuroendocrine cancer, adrenal cancer, thyroid cancer, bone cancer, skin cancer, basal cell carcinoma, squamous cell carcinoma, melanoma, and/or brain tumor.Type: ApplicationFiled: January 27, 2021Publication date: July 29, 2021Inventors: Cheng-Der Tony YU, Jiann-Shiun LAI, I-Ju CHEN, Chiu-Chun LIN
-
Patent number: 11041017Abstract: Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to stage-specific embryonic antigen 4 (SSEA-4) are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as breast cancer, lung cancer, esophageal cancer, rectal cancer, biliary cancer, liver cancer, buccal cancer, gastric cancer, colon cancer, nasopharyngeal cancer, kidney cancer, prostate cancer, ovarian cancer, cervical cancer, endometrial cancer, pancreatic cancer, testicular cancer, bladder cancer, head and neck cancer, oral cancer, neuroendocrine cancer, adrenal cancer, thyroid cancer, bone cancer, skin cancer, basal cell carcinoma, squamous cell carcinoma, melanoma, and/or brain tumor.Type: GrantFiled: March 29, 2017Date of Patent: June 22, 2021Assignee: OBI Pharma, Inc.Inventors: Cheng-Der Tony Yu, Jiann-Shiun Lai, I-Ju Chen, Chiu-Chun Lin
-
Patent number: 11035563Abstract: A light source device includes a substrate, an upper electrode layer and a lower electrode layer respectively disposed on two opposite surfaces of the substrate, a plurality of first conductive posts and second conductive posts embedded in the substrate and having the same number, a light emitter, a surrounding frame surrounding the light emitter, and a light permeable member disposed on the surrounding frame and covering the light emitter. The first conductive posts connect a first upper electrode pad of the upper electrode layer and a first lower electrode pad of the lower electrode layer. The second conductive posts connect a second upper electrode pad of the upper electrode layer and a second lower electrode pad of the lower electrode layer. The light emitter is mounted on the first upper electrode pad and is electrically connected to the second upper electrode pad.Type: GrantFiled: August 8, 2019Date of Patent: June 15, 2021Assignees: LITE-ON OPTO TECHNOLOGY (CHANGZHOU) CO., LTD., LITE-ON TECHNOLOGY CORPORATIONInventors: Hsin-Wei Tsai, I-Ju Chen, Hou-Yen Tsao, Shu-Hua Yang, Yu-Hung Su
-
Patent number: 11000601Abstract: Antibody drug conjugates (ADC's) comprising a drug conjugated to antibody or antigen binding fragments thereof that bind to Globo series antigen disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as sarcoma, skin cancer, leukemia, lymphoma, brain cancer, glioblastoma, lung cancer, breast cancer, oral cancer, head-and-neck cancer, nasopharyngeal cancer, esophagus cancer, stomach cancer, liver cancer, bile duct cancer, gallbladder cancer, bladder cancer, pancreatic cancer, intestinal cancer, colorectal cancer, kidney cancer, cervix cancer, endometrial cancer, ovarian cancer, testical cancer, buccal cancer, oropharyngeal cancer, laryngeal cancer and prostate cancer.Type: GrantFiled: November 21, 2017Date of Patent: May 11, 2021Assignee: OBI PHARMA, INC.Inventors: Michael Nientse Chang, Jiann-Shiun Lai, Wan-Fen Li, I-Ju Chen, Yi-Chien Tsai, Kai-Chuan Chen
-
Publication number: 20210113711Abstract: Antibody drug conjugates (ADC's) comprising a drug conjugated to antibody or antigen binding fragments thereof that bind to Globo series antigen disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as sarcoma, skin cancer, leukemia, lymphoma, brain cancer, glioblastoma, lung cancer, breast cancer, oral cancer, head-and-neck cancer, nasopharyngeal cancer, esophagus cancer, stomach cancer, liver cancer, bile duct cancer, gallbladder cancer, bladder cancer, pancreatic cancer, intestinal cancer, colorectal cancer, kidney cancer, cervix cancer, endometrial cancer, ovarian cancer, testical cancer, buccal cancer, oropharyngeal cancer, laryngeal cancer and prostate cancer.Type: ApplicationFiled: December 23, 2020Publication date: April 22, 2021Inventors: Michael Nientse Chang, Jiann-Shiun Lai, Wan-Fen Li, I-Ju CHEN, Yi-Chien Tsai, Kai-Chuan Chen
-
Patent number: 10980894Abstract: Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to stage-specific embryonic antigen 4 (SSEA-4) are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as breast cancer, lung cancer, esophageal cancer, rectal cancer, biliary cancer, liver cancer, buccal cancer, gastric cancer, colon cancer, nasopharyngeal cancer, kidney cancer, prostate cancer, ovarian cancer, cervical cancer, endometrial cancer, pancreatic cancer, testicular cancer, bladder cancer, head and neck cancer, oral cancer, neuroendocrine cancer, adrenal cancer, thyroid cancer, bone cancer, skin cancer, basal cell carcinoma, squamous cell carcinoma, melanoma, and/or brain tumor.Type: GrantFiled: June 1, 2018Date of Patent: April 20, 2021Assignee: OBI PHARMA, INC.Inventors: Cheng-Der Tony Yu, Jiann-Shiun Lai, I-Ju Chen, Chiu-Chun Lin
-
Patent number: D1018524Type: GrantFiled: January 20, 2020Date of Patent: March 19, 2024Assignee: COMPAL ELECTRONICS, INC.Inventors: Jyh-Chyang Tzou, Shi-Kuan Chen, I Ta Tsai, Meng Ju Wu
-
Patent number: D1024051Type: GrantFiled: August 10, 2021Date of Patent: April 23, 2024Assignee: Acer IncorporatedInventors: Hui-Jung Huang, Hong-Kuan Li, I-Lun Li, Ling-Mei Kuo, Kuan-Ju Chen, Fang-Ying Huang, Kai-Hung Huang, Szu-Wei Yang, Kai-Teng Cheng